

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

In re Application of:)
)
 JAMES HILL, ET AL.)
)
 U.S. Serial No. **10/525,057**) Art Unit: **1645**
)
 U.S. Filing Date: **September 14, 2005**)
)
 For: **VACCINE AGAINST YERSINIA**) Examiner: **Gangle, Brian. J.**
 COMPRISING ONE OR TWO ANTI- BODIES,)
 ONE SPECIFIC FOR *YERSINIA PESTIS*)
 F1-ANTIGEN AND THE OTHER ONE FOR)
 ***YERSINIA PESTIS* V-ANTIGEN**)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In the Election/Restriction Requirement mailed February 8, 2007, the Examiner required restriction of the above-identified patent application to one of the following groups of claims:

Group I: Claims 17-19, 21 and 24, drawn to methods of treating a *Yersinia pestis* infection comprising administering an antibody specific for *Yersinia pestis* F1 antigen;

Group II: Claims 17-21 and 23-24, drawn to methods of treating a *Yersinia pestis* infection comprising administering an antibody specific for *Yersinia pestis* V antigen;

Group III: Claims 17-24, drawn to methods of treating a *Yersinia pestis* infection comprising administering a combination of an antibodies specific for *Yersinia pestis* V antigen and antibodies specific for *Yersinia pestis* F1 antigen;

I hereby certify that this correspondence is being electronically filed with the United States Patent & Trademark Office on March 9, 2007 through its EFS-Web electronic filing system.


Zara A. Doddridge, Ph.D. – Reg. No. 59,098

Group IV: Claims 25-29 and 31, drawn to pharmaceutical compositions comprising antibodies specific for *Yersinia pestis* V antigen and antibodies specific for *Yersinia pestis* F1 antigen; and

Group V: Claims 30 and 32, drawn to methods of immunizing against *Yersinia pestis* comprising administering a pharmaceutical composition comprising antibodies specific for *Yersinia pestis* V antigen and antibodies specific for *Yersinia pestis* F1 antigen.

In response to the Restriction Requirement, Applicants elect Group III (Claims 17-24) directed to methods of treating a *Yersinia pestis* infection comprising administering a combination of an antibodies specific for *Yersinia pestis* V antigen and antibodies specific for *Yersinia pestis* F1 antigen.

No additional fees are believed due; however the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account number 11-0855.

Respectfully submitted,



By: Zara A. Doddridge, Ph.D.
Reg. No. 59,098

KILPATRICK STOCKTON LLP
Suite 2800
1100 Peachtree Street
Atlanta, Georgia 30309-4530
Telephone: 404-815-6473
Facsimile: 404-541-3435
Our Docket: 41577-312173